1. Home
  2. PMI vs WHWK Comparison

PMI vs WHWK Comparison

Compare PMI & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PMI

Picard Medical Inc.

N/A

Current Price

$0.95

Market Cap

202.7M

Sector

N/A

ML Signal

N/A

WHWK

Whitehawk Therapeutics Inc.

HOLD

Current Price

$3.49

Market Cap

179.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMI
WHWK
Founded
1981
2007
Country
United States
United States
Employees
N/A
22
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
202.7M
179.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PMI
WHWK
Price
$0.95
$3.49
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
159.2K
172.8K
Earning Date
03-25-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$1.39
52 Week High
$13.68
$4.40

Technical Indicators

Market Signals
Indicator
PMI
WHWK
Relative Strength Index (RSI) 37.80 50.94
Support Level N/A $1.84
Resistance Level $1.37 $3.77
Average True Range (ATR) 0.10 0.24
MACD 0.01 -0.06
Stochastic Oscillator 6.89 39.78

Price Performance

Historical Comparison
PMI
WHWK

About PMI Picard Medical Inc.

Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing an implantable Total Artificial Heart. It is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including TAH. The TAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.

About WHWK Whitehawk Therapeutics Inc.

Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.

Share on Social Networks: